The physiological concern with any bioactive peptide used chronically is receptor desensitization, metabolic accumulation of degradation byproducts, and potential downstream endocrine effects that manifest only after sustained signaling pathway activation
Theoretically, once the senescent cell burden is reduced to a low, manageable level, the benefits would plateau until those cells begin to re-accumulate
D., He, L., Hover, L
MAP3K7, Mitogen-Activated Protein Kinase Kinase Kinase 7
While animal studies consistently demonstrate beneficial effects across diverse injury models and tissue types, the absence of adequately powered, controlled human clinical trials prevents definitive conclusions about efficacy in human disease
These differences shed light on the impact of peptide size and complexity on therapeutic potential and guide the selection of peptides best suited for specific wound types